Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort

Thymic epithelial tumors (TETs) are rare malignancies that may be aggressive and difficult to treat. In the advanced setting, systemic treatments may be delivered as primary therapy before surgery or definitive radiotherapy, as exclusive treatment when no focal treatment is feasible, or in the setti...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2018-11, Vol.13 (11), p.1762-1770
Main Authors: Merveilleux du Vignaux, Claire, Dansin, Eric, Mhanna, Laurent, Greillier, Laurent, Pichon, Eric, Kerjouan, Mallorie, Clément-Duchêne, Christelle, Mennecier, Bertrand, Westeel, Virginie, Robert, Marie, Quantin, Xavier, Zalcman, Gérard, Thiberville, Luc, Lena, Hervé, Molina, Thierry, Calcagno, Fabien, Fournel, Pierre, Mazières, Julien, Besse, Benjamin, Girard, Nicolas
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Chemotherapy
Cohort Studies
Female
Humans
Life Sciences
Male
Middle Aged
Neoplasms, Glandular and Epithelial - pathology
Neoplasms, Glandular and Epithelial - therapy
Network
Prospective Studies
Recurrence
Thymic Carcinoma
Thymoma
Thymus Neoplasms - pathology
Thymus Neoplasms - therapy
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thymic epithelial tumors (TETs) are rare malignancies that may be aggressive and difficult to treat. In the advanced setting, systemic treatments may be delivered as primary therapy before surgery or definitive radiotherapy, as exclusive treatment when no focal treatment is feasible, or in the setting of recurrences. Réseau tumeurs THYMIques et Cancer (RYTHMIC) is the nationwide network for TETs in France. The objective of the study was to describe the modalities and analyze the efficacy of systemic treatments for patients with advanced TETs included in the RYTHMIC prospective database hosted by the French Thoracic Cancer Intergroup. All consecutive patients for whom systemic treatment was discussed at the RYTHMIC multidisciplinary tumor board from 2012 to 2015 and who received at least one cycle of treatment were included. The main end points were objective response and progression-free survival (PFS). A total of 236 patients were included in this analysis. Of those 236 patients, 91 received primary chemotherapy, leading to response rates of 83% for thymomas and 75% for thymic carcinomas and a median PFS of 23.2 months. A strong predictor of longer PFS was histologic type of thymoma (p 
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2018.08.005